Analysis of Decitabine Therapeutic Effeicacy for Patients with Relapsed MDS/AML and High-Risk AML Patients after HSCT.
10.7534/j.issn.1009-2137.2020.01.042
- Author:
Qing-Yun WANG
1
;
Ze-Yin LIANG
1
;
Yu-Jun DONG
1
;
Yue YIN
1
;
Qian WANG
1
;
Wei LIU
1
;
Wei-Lin XU
1
;
Yuan LI
2
;
Han-Yun REN
3
Author Information
1. Department of Hematology，The First Hospital of Peking University，Beijing 100034，China.
2. Department of Hematology，The First Hospital of Peking University，Beijing 100034，China,E-mail: drliyuan75@163.com.
3. Department of Hematology，The First Hospital of Peking University，Beijing 100034，China,E-mail: renhy0813@163.com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):248-254
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the therapeutic efficacy of using decitabine as maintenance therapy for patients with relapsed MDS/AML and as prophylactic therapy for patients with high-risk AML after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODS:Clinical data of 10 patients with MDS/AML from November 2016 to May 2018 were analyzed retrospectively. Among 10 patients there were 4 cases of AML, 2 cases of MDS, and 4 cases of AML transformed from MDS (t-AML). The 10 patients were devided into 2 groups: the relapsed group (n=8) and the prophylactic group (n=2). In relapsed group the decitabine was used as maintenance therapy after achieved complete remission (CR) with decitabine chemotherapy. In prophylactic group the decitabine was used as prophylactic therapy if the patients didn't appear the symptom of graft-versus- host-disease (GVHD) during 30 to 45 d after allo-HSCT. Eight patients received G-CSF-mobilized donor lymphocyte infusion (DLI). The dosage of decitabine for maintenance therapy and prophylactic therapy was 5 mg/m for 7 to 10 days every 4 to 6 weeks, as 1 cycle, amount to 3 to 7 cycles. The dosage was adjusted by the endurance of patients.
RESULTS:Until Nov 30, 2018, 7 out of 10 patients survived. The average survival time was 15.5±1.9 months. 1-year OS rate was 64.0%. Six patients appeared aGVHD, and four patients appeared cGVHD.
CONCLUSION:The usage of decitabine combined with DLI in patients with relapsed MDS/AML and high-risk AML after allo-HSCT can prolong lives of patients, reduce relapsed rate, and provide the probability for long time survival.
